A newly discovered enzyme plays a critical role in triggering the body’s first line of defense against viruses, according to a study published in Nature Cell Biology on March 10, 2026. The research identifies ANKIB1 as a key regulator of the innate immune response, potentially opening avenues for fresh therapies against viral infections, cancer, and inflammatory diseases.
The innate immune system relies on sensors called pattern recognition receptors (PRRs) to detect invading pathogens. These receptors initiate signaling pathways that ultimately lead to the production of interferons, which orchestrate the immune response. While the importance of this process was known, the precise mechanisms remained unclear. This discovery sheds light on how that signal is initiated and amplified.
A New Component of the Immune Code
Researchers from the University of Cologne, in collaboration with teams in Spain and the United Kingdom, found that ANKIB1 catalyzes the formation of lysine-11 (K11)-linked ubiquitin chains – a specific molecular modification that acts as a platform for activating type I and type III interferons, crucial antiviral messengers. “We have discovered that ANKIB1 decides when the alarm clock for immune cells rings and also how loud this wake-up call is,” said Henning Walczak, Alexander von Humboldt Professor of Biochemistry and Director of the Institute of Biochemistry I at the Medical Faculty of the University of Cologne.
The findings resolve a long-standing puzzle in innate immunity and offer new perspectives for developing innovative therapies. “With K63- and M1-Ubiquitin, only two letters of the ubiquitin signal code were previously known. With the discovery of K11-Ubiquitin as a third letter of the ubiquitin alphabet, we are one crucial step closer to deciphering the ubiquitin code of cellular signal transduction,” explained Dr. Eva Rieser, a biochemist and immunologist at the University of Cologne.
Balancing the Interferon Response
Experiments using cell cultures and animal models confirmed that the ANKIB1–K11-Ubiquitin–OPTN–TBK1–IRF3 signaling pathway is essential for alerting the immune system to viral infections. The team demonstrated that ANKIB1 is crucial for fighting infection with herpes simplex virus 1, the virus that causes cold sores. Mice lacking ANKIB1 were unable to produce the interferon needed to activate their immune systems, leading to fatal infections.
Although, an overabundance of interferon can contribute to severe inflammatory diseases. Interestingly, mice without ANKIB1 survived a typically fatal inflammatory condition in a laboratory model, suggesting that ANKIB1 also plays a role in regulating excessive interferon production. These results indicate that ANKIB1 plays a central role in both necessary and pathological interferon reactions.
Boosting the Immune Attack on Cancer
The research also has implications for cancer treatment. Many tumors exploit the chronic activation of innate immune pathways – particularly those triggered by cGAS-STING and various Toll-like receptors – to create an environment that suppresses the immune system’s ability to attack cancer cells. “Although the work is based on fundamental biochemical and immunological findings, it also has important implications for cancer diseases, as this signaling cascade is central to the dialogue between tumor and immune cells,” said Professor Julian Pardo from the Aragón Health Research Institute, CIBERINFEC and the University of Zaragoza in Spain, who contributed to the study.
Identifying ANKIB1 and K11-Ubiquitin as key factors in interferon induction opens new approaches to understanding how cancer cells regulate these pathways to their advantage and how this balance could be therapeutically restored. Manipulating ANKIB1 activity could potentially “reprogram” the immune system within tumors, either enhancing interferon responses to support immunotherapy or suppressing excessive inflammation that leads to immune exhaustion and tissue damage.
Signal Pathways in Neuroinflammation
Chronic, low-grade activation of innate immune system sensors in the brain is also thought to be a common feature of neurodegenerative diseases like Alzheimer’s and Parkinson’s, where interferon signals have been shown to promote inflammation and nerve cell loss. The study suggests that ANKIB1 and K11-Ubiquitin regulate these interferon pathways, providing a framework for understanding how inflammatory signals are synchronized in the brain and how aberrant interferon production contributes to neurodegeneration.
“By precisely identifying the ubiquitin chain type and the enzyme that creates it, a complex immune cascade is transformed into a clearly defined, therapeutically targetable process,” Walczak explained. This insight could facilitate the development of new therapies and their application in clinical practice for numerous diseases.
ANKIB1 as a Therapeutic Target
Instead of broadly suppressing the immune system, which could compromise essential defenses, inhibiting the catalytic activity of ANKIB1 or promoting its degradation could be sufficient to treat diseases driven by excessive interferon-induced inflammation or autoimmune reactions. Conversely, temporarily increasing ANKIB1 activity or stabilizing K11-Ubiquitin could be used to boost the immune system against viruses or cancer cells.
This work was the result of close collaboration with the teams of Professor Julian Pardo in Zaragoza and Professor Antonio Alcamí from the Severo Ochoa Center for Molecular Biology of the Spanish National Research Council (CSIC) in Madrid, as well as with Professor Brian Ferguson from the University of Cambridge, who provided crucial in vivo and in vitro infection models and virological expertise.
Signal Transduction Target Ther. 2025 Jul 11;10:216. Doi: 10.1038/s41392-025-02264-1
Source: University of Cologne
Original publication: Alexis Betrancourt et al.; Lysine-11 ubiquitination drives type-I/III interferon induction by cGAS–STING and Toll-like receptors 3 and 4; nature cell biology, 2026, DOI: 10.1038/s41556-026-01886-z
